The Mission Marketing Group plc ('the missiontm' or "the Company", AIM: TMMG), the marketing communications and advertising group, today issues a trading update for the year ended 31 December 2016. We are pleased to report that the missiontm has again experienced a strong second half, and accordingly the Company expects 2016 to be a year of further growth, both in terms of operating income ("revenue") and profitability. Headline profit before tax for the year to 31 December is expected to be 8% higher, at £7.0m. The Company's balance sheet remains strong and, despite settling over £3m of acquisition obligations during the year, gearing and debt leverage ratios are expected to be lower than those of 2015 and comfortably within the Board's target. Headline profits are calculated before acquisition adjustments, losses from start-up activities and exceptional restructuring costs, if any. These adjustments are expected to be at a similar level to 2015, when they totalled £1.3m. The Board remains committed to increasing shareholder value and intends to launch a growth share scheme later this quarter to incentivise board and operational management. The Company expects to announce its preliminary results on 23 March 2017. David
Proposed Consolidation of Share Capital Shareholders' Circular and Notice of General Meeting On 23 November 2016, Verona Pharma plc (AIM: VRP) ("Verona Pharma" or the "Company") announced that it plans to conduct a registered initial public offering in the United States. Further to that announcement, the Company announces that it will today publish and post to shareholders an explanatory circular (the "Circular") and a form of proxy. The Circular contains a letter from the Chairman which provides further information on the potential United States registered public offering of ordinary shares in the capital of the Company to be represented in the form of American depositary shares and, as applicable, a potential concurrent private placement of ordinary shares in the capital of the Company (together the "Global Offering"). Prior to undertaking the Global Offering, and in order to achieve an appropriate listing price for the American depositary shares, the Company proposes to undertake a consolidation of every 50 ordinary shares of £0.001 each in issue at 6.00 p.m. on 10 February 2017 into one ordinary share of £0.05 each (the "Consolidation"). As at 17 January 2017, the Company had 2,568,053,160 ordinary shares in issue, each with a nominal value of £0.001. The Circular incorporates a notice convening a General Meeting to be held at Shakespeare Martineau LLP, Allianz House, 6th Floor, 60 Gracechurch Street, London, EC3V 0HR at 12.00 p.m. (noon) on 8 February 2017 in order for shareholders to vote upon the resolutions considered necessary to facilitate the Global Offering. Amongst the resolutions to be considered at the General Meeting are resolutions to approve the Consolidation and the adoption of new articles of association. An electronic copy of the Circular will be available on the Company's website at: http://www.veronapharma.com.
Verona Pharma plc (AIM: VRP), the drug development company focused on first-in-class medicines to treat respiratory diseases, announces that it has issued 2,000,000 new ordinary shares in the capital of the Company (the ?New Shares?) following an exercise of share options by a former employee. Application has been made to the London Stock Exchange for the New Shares to be admitted to trading on AIM, with dealings expected to commence on 6 January 2017 (?Admission?). Following Admission, the Company will have a total of 2,568,053,160 Ordinary Shares in issue each carrying one voting right. The Company does not hold any Ordinary Shares in Treasury. This figure of 2,568,053,160 Ordinary Shares may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.
The Mission Marketing Group plc ("TMMG" or "the missiontm"), the marketing communications and advertising group was notified on 24 November 2016 that on that day, Robert Day, an Executive Director of the mission™, purchased 11,600 ordinary shares of 10p each in the capital of the Company ("Ordinary Shares") at a price of 41.95 pence per Ordinary Share. As a result, Mr. Day is now interested in 6,153,524 Ordinary Shares representing 7.32 per cent. of the total voting rights of the mission™.
All ticking over nicely. Div 67pc up! Great work by the team! Will the uptick in price hold?
The Mission Marketing Group plc ("TMMG" or "the missiontm"), the marketing communications and advertising group, sets out its unaudited interim results for the six months ended 30 June 2016. Trading · Some great new business wins in the period, including Fuji Xerox, Golden Wonder, Greene King, Halfords, Mondelez, O2 and Sky Betting & Gaming · Good progress made upscaling people, systems and technology · Recent acquisitions trading well and global capabilities strengthened · Expect to have a strong second-half bias as in previous years and remain confident for full year outlook Income statement · Revenue up 10% to £32.4m (2015: £29.5m) · Headline profit before tax up 10% to £2.6m (2015: £2.3m*) · Reported profit before tax up 14% to £2.0m (2015: £1.7m*) · Headline diluted EPS up 15% to 2.33 pence (2015: 2.03 pence*) Balance sheet and cash flow · Cash inflows from operating activities of £4.8m (2015: £2.3m) · Acquisition obligations of £3.0m settled since year-end · Period-end acquisition obligations reduced to £5.4m, of which only £2.5m due within one year · Net bank debt reduced by £1.5m in the six months to £9.4m · Debt levels continue to reduce and are comfortably within the Board's limits Dividend · Interim dividend increased by 67% to 0.5p (2015: 0.3p) · Payable on 2 December 2016 to shareholders on the register at 4 November 2016
12 September 2016, Cardiff – Verona Pharma plc (AIM: VRP), a drug development company focused on first-in-class medicines to treat respiratory diseases, today announces the appointment of Vikas Sinha to the Board of Verona Pharma as a Non-Executive Director, with immediate effect. Vikas (aged 53) has over 20 years of experience working in senior finance roles in the life sciences industry. He is currently Executive Vice President and Chief Financial Officer of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), one of the world's leading rare disease companies with a market cap of approximately USD30 billion. Vikas joined Alexion in 2005 and is responsible for global financial management, information technology, corporate and strategic development, treasury, internal audit and investor relations. Prior to Alexion, Vikas spent 11 years at Bayer AG where he held various positions within the company in the United States, Canada, Japan and Germany. His last role was Vice President and Chief Financial Officer of Bayer Pharmaceuticals Corporation, USA, where he was responsible for financial management and strategic planning in North America.
Jan-Anders Karlsson purchased 600,000 Ordinary Shares at 3.249 today.
Trading update and notice of results The Mission Marketing Group plc ('the missiontm', or "the Group" AIM: TMMG), the marketing communications and advertising group, today issues a trading update for the six months ended 30 June 2016. The Board is pleased to report that we again expect both revenue and profit for the first half of 2016 to show double digit growth over the equivalent period last year, benefiting from both organic growth and the acquisitions made in the second half of last year. The Group's net debt fell £1.5m after making cash consideration payments totalling £2.6m in the period, reflecting strong working capital inflows. Net debt was £9.4m at 30 June 2016 and the Group's leverage ratios (the ratios of net bank debt and total debt to EBITDA) have both reduced during the six month period and remain comfortably within the limits set by the Board for these key performance indicators. We expect our results for the year to 31 December 2016 to again have a significant bias towards the second half and we look forward to further progress over the remainder of the year. The Group expects its interim results, for the six months ended 30 June 2016, to be announced on 22 September.
Did anyone go? If so can they share any feedback? Many thanks
I think the client list, boards acqumin, debt position and growth Has been tremendous. Bit of self promotion to the mkt wouldn't go a miss, very tightly held this stock with a good % held by employees and the bod. Maybe the lack of free float stock holds this back. As we grow we'll become a takeover target or a very nice steady business with steady div growth. Happy to hold and see where we head.
Excellent I agree, just a shame the sp doesn't reflect it!
Financial headlines · Operating income ("revenue") up 11% to £61.0m (2014: £55.0m) · Headline trading profit (operating profit before central costs) up 11% to £8.5m (2014: £7.7m) · Headline profit before tax up 17% to £6.5m (2014: £5.5m) · Headline diluted EPS up by 15% to 5.91 pence (2014: 5.13 pence) · Full year dividend up by 9% to 1.2p (2014: 1.1p) · Total cash investment in growth: £4.0m (on acquisitions, start-ups and capex) · Nearly £1m of new business generated from cross-Agency referrals · Almost 60% of revenue came from Clients of 5 or more years; over 20% from Clients of 20+ years standing · Good revenue visibility into 2016, which has started as expected
Steady as she goes... Building long term value
The Mission Marketing Group plc Acquisition of Chapter Agency Limited The Mission Marketing Group plc ('the missiontm', "the Company", AIM: TMMG), the marketing communications and advertising group, is pleased to announce that it has acquired Chapter Agency Limited which includes the recently acquired Bell and Watson Limited (together "Chapter"). Initial consideration of £1.3m is payable in cash on completion. Further consideration of up to £3.7m is payable subject to financial performance in 2015, 2016, 2017 and 2018, of which the first £0.2m will be payable in ordinary shares of 10 pence each in the capital of the Company (the "Acquisition"). About Chapter Established in 2009, Chapter is a Midlands-based advertising agency employing 29 people and has an extensive client base including Nissan, Yardley, Topps Tiles, Crowdcube, Calor and Virgin Trains. Since launching, it has been voted National Advertising Agency of the Year at the Marketing Industry Awards and this month was the most nominated Agency at the prestigious Cream Awards 2015, winning in seven categories. Chapter Agency Limited also recently acquired Bell and Watson Limited, a consultancy that delivers specialist digital marketing services.
Yes more positives adding. I agree with you very undervalued, nice to see a small up tick. Still happy to hold, starting to wonder if this could be a take over target in the future especially with the excellent business model and low valuation..
The Mission Marketing Group plc ("TMMG" or "the missiontm"), the marketing communications and advertising group, sets out its interim results for the six months ended 30 June 2015. Trading · Continued growth, both organic and from acquisitions · Some great new Client wins in the period, including Ask, Autoline, BMW, Brewin Dolphin, British Airways, Diageo, Muller Wiseman, RAC, Sage, SAS and Siemens · Full year again expected to have a strong second-half bias - trading remains in line · Continue to seek suitable acquisitions Income Statement · Operating income (Revenue) up 12% to £29.5m (2014: £26.3m) · Headline operating profit up 15% to £2.4m (2014: £2.1m) · Headline profit before tax up 20% to £2.2m (2014: £1.8m) · Headline Diluted EPS up 12% to 1.88 pence (2014: 1.68 pence) Balance sheet and cash flow · Net bank debt reduced by £1.5m in the six months to £7.9m · Bank debt leverage ratio maintained below x1.25 · Total debt leverage ratio below x1.5 Dividend · Significant increase in interim dividend to 0.3p (2014: 0.25p) · Payable on 4 December 2015 to shareholders on the register at 6 November 2015
I agree, surprise really it dipped so low. Another couple of days like this would be most desirable!
Revenue and profit for the first half of 2015 are expected to show double digit growth over the equivalent period last year, benefiting from both organic growth and the acquisitions made in the second half of last year. The group's net debt fell from £9.4m at 31 December 2014 to £8.3m at 30 June 2015, and the group's leverage ratios (the ratios of net bank debt and total debt to EBITDA) remain comfortably within the limits set by the Board for these key performance indicators. The group has made five acquisitions over the last twelve months, merged two of its existing Integrated Generalist Agencies and launched a new Specialist Agency from scratch. It has been a busy time and our recent focus has been on bedding these new businesses into the group. Looking to the future, we will seek to exploit the opportunities for further growth these new businesses bring and in addition we will continue to explore opportunities to extend our range and reach further in response to Client demand. Our results for the year to 31 December 2015 are again expected to have a bias towards the second half and the Board remains confident of meeting market expectations for the full year.
The Mission Marketing Group plc ('the missiontm', AIM: TMMG), the marketing communications and advertising group, announces that it was informed on 31 March 2015 that David Morgan, Chairman to the Company, purchased 40,000 ordinary shares of 10 pence each in the capital ("Ordinary Shares") of the Company at a price of 43 pence per Ordinary Share. Following this purchase Mr Morgan now holds 6,129,533 Ordinary Shares, representing 7.3% of its issued share capital.